Vertex Pharmaceuticals Incorporated
VRTX
$398.43
-$2.33-0.58%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 968.80M | 1.04B | 915.70M | 699.80M | 818.90M |
| Total Depreciation and Amortization | 47.20M | 42.10M | 41.40M | 38.80M | 38.40M |
| Total Amortization of Deferred Charges | 11.80M | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.70M | 2.10M | -68.10M | 22.40M | 312.00M |
| Change in Net Operating Assets | -838.90M | 188.90M | 245.40M | 138.90M | -90.90M |
| Cash from Operations | 234.60M | 1.27B | 1.13B | 899.90M | 1.08B |
| Capital Expenditure | -58.10M | -40.60M | -59.60M | -42.10M | -33.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -828.40M | -77.10M | -244.30M | -1.79B | 209.20M |
| Cash from Investing | -886.50M | -117.70M | -303.90M | -1.83B | 175.60M |
| Total Debt Issued | 1.80M | -- | -- | -- | 3.50M |
| Total Debt Repaid | -12.00M | -11.30M | -11.00M | -10.60M | -10.40M |
| Issuance of Common Stock | 46.40M | 15.40M | 58.60M | 14.20M | 51.60M |
| Repurchase of Common Stock | -152.70M | -170.20M | -31.40M | -299.40M | -2.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.30M | 1.10M | 1.10M | 1.10M | -2.40M |
| Cash from Financing | -119.80M | -165.00M | 17.30M | -294.70M | 40.20M |
| Foreign Exchange rate Adjustments | 27.40M | -22.50M | 10.00M | 12.00M | 40.80M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -744.30M | 963.20M | 857.80M | -1.22B | 1.34B |
